Covered, compounding — on adjusted earnings. A 2.10% yield at about a 45% payout of adjusted earnings is covered income with room to raise: $0.82 a quarter, raised 3.8% beginning in 2026 for a 10th consecutive year of increases. Reported GAAP earnings distort the payout — MarketBeat shows it negative after charges — so the House grades coverage on adjusted earnings and cash flow, and says so: Q2 2026 product sales excluding Veklury grew 10% to $7.6 billion, and 2026 product-sales guidance was raised to $30.1–$30.4 billion.
Key risk: HIV concentration — Biktarvy and the HIV franchise still carry the portfolio, so patent, competition, or treatment-shift risk in HIV reaches the dividend faster than the oncology and liver-disease growth can offset it.
Changes if: adjusted earnings stop covering the $3.28 annual rate, or the raise streak breaks. The adjusted payout, not the GAAP figure, is the tripwire here.
- !Payout-coverage check: About 45% of adjusted earnings and about 40% of free cash flow — covered on the basis the company itself guides on. The GAAP payout reads negative because charges sit in reported earnings, so a GAAP-only screen misreads this card.
- ✓Yield check: 2.10% indicated — $0.82/qtr × 4 at the $156.04 close on Oct. 23, 2026. Real, earned yield for a single stock, not a special or a return of capital.
- ✓Dividend growth check: 10 consecutive years of increases; the 2026 raise lifted the quarterly dividend 3.8%, from $0.79 to $0.82.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.